We demonstrated that both ritanserin and another serotonin receptor and DGKα inhibitor, R-59-022, synergised with low doses of trametinib in SCRIBRNAi/H-RASG12V cells (as well as in SCRIBRNAi cells and H-RASG12V cells) – doses at which normal cells were not greatly affected, suggesting that these drug combinations could be used to specifically target Ras-driven and/or polarity-impaired cancer cells. The gene discussed is DGKA; the disease is cancer.